The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
Abstract
OBJECTIVES: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD. DESIGN: A cohort study including 6843 HIV-positive persons with at least three serum creatinine measurements and corresponding body weight measurements from 2004 onwards. METHODS: CKD was defined as either confirmed (two measurements >or=3 months apart) estimated glomerular filtration rate (eGFR) of 60 ml/min per 1.73 m or below for persons with baseline eGFR of above 60 ml/min per 1.73 m or confirmed 25% decline in eGFR for persons with baseline eGFR of 60 ml/min per 1.73 m or less, using the Cockcroft-Gault formula. Poisson regression was used to determine factors associated with CKD. RESULTS: Two hundred and twenty-five (3.3%) persons progressed to CKD during 21 482 person-years follow-up, an incidence of 1.05 per 100 person-years follow-up [95% confidence interval (CI) 0.91-1.18]; median follow-up was 3.7 years (interquartile range 2.8-5.7). After adjustment for traditional factors associated with CKD and other confounding variables, increasing cumulative exposure to tenofovir [incidence rate ratio (IRR) per year 1.16, 95% CI 1.06-1.25, P < 0.0001), indinavir (IRR 1.12, 95% CI 1.06-1.18, P < 0.0001), atazanavir (IRR 1.21, 95% CI 1.09-1.34, P = 0.0003) and lopinavir/r (IRR 1.08, 95% CI 1.01-1.16, P = 0.030) were associated with a significantly increased rate of CKD. Consistent results were observed in wide-ranging sensitivity analyses, although of marginal statistical significance for lopinavir/r. No other antiretroviral drugs were associated with increased incidence of CKD. CONCLUSION: In this nonrandomized large cohort, increasing exposure to tenofovir was associated with a higher incidence of CKD, as was true for indinavir and atazanavir, whereas the results for lopinavir/r were less clear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Levey, A. S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D. D. E., Hostetter, T. H., Lameire, N., & Eknoyan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00365.x · Cited by 3,946
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., Monforte, A. D., Knysz, B., Dietrich, M., Phillips, A., & Lundgren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13802-0 · Cited by 1,241
Self-citationTenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Measurement of renal function in chronic renal disease
Levey, P. D. A. S. (1990) · Kidney International · doi:10.1038/ki.1990.182 · Cited by 564
Structural-functional correlations in renal disease
Schainuck, L. I., Striker, G. E., Cutler, R. E., & Benditt, E. P. (1970) · Human Pathology · doi:10.1016/s0046-8177(70)80061-2 · Cited by 462
Verhave, J. C., Fesler, P., Ribstein, J., du Cailar, G., & Mimran, A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.05.011 · Cited by 386
Karras, A., Lafaurie, M., Furco, A., Bourgarit, A., Droz, D., Sereni, D., Legendre, C., Martinez, F., & Molina, J. (2003) · Clinical Infectious Diseases · doi:10.1086/368314 · Cited by 361
Fanconi syndrome and renal failure induced by tenofovir: A first case report
Verhelst, D., Monge, M., Meynard, J.-L., Fouqueray, B., Mougenot, B., Girard, P.-M., Ronco, P., & Rossert, J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36924 · Cited by 349
The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection
Szczech, L. A., Gupta, S. K., Habash, R., Guasch, A., Kalayjian, R., Appel, R., Fields, T. A., Svetkey, L. P., Flanagan, K. H., Klotman, P. E., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00865.x · Cited by 340
Marras, D., Bruggeman, L. A., Gao, F., Tanji, N., Mansukhani, M. M., Cara, A., Ross, M. D., Gusella, G. L., Benson, G., D'Agati, V. D., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-522 · Cited by 303
Goicoechea, M., Liu, S., Best, B., Sun, S., Jain, S., Kemper, C., Witt, M., Diamond, C., Haubrich, R., Louie, S., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/524061 · Cited by 299
Prevalence of Chronic Kidney Disease and Associated Risk Factors—United States, 1999-2004
(2007) · JAMA · doi:10.1001/jama.297.16.1767 · Cited by 254
Chronic renal failure among HIV-1-infected patients
Mocroft, A., Kirk, O., Gatell, J., Reiss, P., Gargalianos, P., Zilmer, K., Beniowski, M., Viard, J.-P., Staszewski, S., & Lundgren, J. D. (2007) · AIDS · doi:10.1097/qad.0b013e3280f774ee · Cited by 228
Self-citationLucas, G. M., Lau, B., Atta, M. G., Fine, D. M., Keruly, J., & Moore, R. D. (2008) · The Journal of Infectious Diseases · doi:10.1086/587994 · Cited by 215
The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients
Kiser, J., Carten, M., Aquilante, C., Anderson, P., Wolfe, P., King, T., Delahunty, T., Bushman, L., & Fletcher, C. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100269 · Cited by 206
Szczech, L. A., Hoover, D. R., Feldman, J. G., Cohen, M. H., Gange, S. J., Gooze, L., Rubin, N. R., Young, M. A., Cai, X., Shi, Q., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424013 · Cited by 184
HIV-1-associated nephropathy and response to highly-active antiretroviral therapy
Wali, R. K., Drachenberg, C. I., Papadimitriou, J. C., Keay, S., & Ramos, E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24037-2 · Cited by 179
Recent Progress in HIV-Associated Nephropathy
Wyatt, C. M., Meliambro, K., & Klotman, P. E. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-041610-134224 · Cited by 173
Development of Proteinuria or Elevated Serum Creatinine and Mortality in HIV-Infected Women
Gardner, L. I., Holmberg, S. D., Williamson, J. M., Szczech, L. A., Carpenter, C. C. J., Rompalo, A. M., Schuman, P., & Klein, R. S. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200302010-00013 · Cited by 172
Reid, A., Stöhr, W., Walker, A. S., Williams, I. G., Kityo, C. M., Hughes, P. J., Kambugu, A., Gilks, C. F., Mugyenyi, P. N., Munderi, P., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/533468 · Cited by 156
Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients
Horberg, M. A., Tang, B. T., Towner, W. J., Silverberg, M. J., Bersoff‐Matcha, S. J., Hurley, L. B., Chang, J., Blank, J., Quesenberry, C. P., & Klein, D. B. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181be6be2 · Cited by 146
The HIV-associated renal diseases: Current insight into pathogenesis and treatment
Weiner, N. J., Goodman, J. W., & Kimmel, P. L. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00901.x · Cited by 139
Recent Progress in HIV-Associated Nephropathy
Ross, M. J., & Klotman, P. E. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000040750.40907.99 · Cited by 133
Spectrum of chronic kidney disease in HIV‐infected patients
Campbell, L., Ibrahim, F., Fisher, M., Holt, S. G., Hendry, B., & Post, F. A. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00691.x · Cited by 132
Renal function with use of a tenofovir-containing initial antiretroviral regimen
Gallant, J. E., & Moore, R. D. (2009) · AIDS · doi:10.1097/qad.0b013e32832c96e9 · Cited by 129
HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy
Choi, A. I., Shlipak, M. G., Hunt, P. W., Martin, J. N., & Deeks, S. G. (2009) · AIDS · doi:10.1097/qad.0b013e3283313c91 · Cited by 128
Tashima, K. T., Horowitz, J. D., & Rosen, S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360215 · Cited by 120
Chan‐Tack, K. M., Truffa, M. M., Struble, K. A., & Birnkrant, D. B. (2007) · AIDS · doi:10.1097/qad.0b013e32813aee35 · Cited by 118
Chugh, S. S., Bird, R., & ALEXANDER, E. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360214 · Cited by 113
Wyatt, C. M., Malvestutto, C., Coca, S. G., Klotman, P. E., & Parikh, C. R. (2008) · AIDS · doi:10.1097/qad.0b013e32830e0152 · Cited by 111
Biesen, W. V., Vanholder, R. C., Veys, N., Verbeke, F., Delanghe, J., Bacquer, D. D., & Lameire, N. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi185 · Cited by 111
Tenofovir-related nephrotoxicity in HIV-infected patients
Barrios, A., García-Benayas, T., González‐Lahoz, J., et al. (2004) · AIDS · doi:10.1097/00002030-200404090-00019 · Cited by 109
Incidence of and risk factors for tenofovir‐induced nephrotoxicity: a retrospective cohort study
Antoniou, T., Raboud, J., Chirhin, S., Yoong, D., Govan, V., Gough, K. A., Rachlis, A., & Loutfy, M. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00308.x · Cited by 105
Protease inhibitors are associated with a slowed progression of HIV-related renal diseases
Szczech, L. A., Edwards, L. J., Sanders, L. L., van der Horst, C., Bartlett, J. A., Heald, A. E., & Svetkey, L. P. (2002) · Clinical Nephrology · doi:10.5414/cnp57336 · Cited by 103
Winston, A., Amin, J., Mallon, P. W. G., Marriott, D., Carr, A. D., Cooper, D., & Emery, S. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00349.x · Cited by 94
Cheng, J.-T., Anderson, H. L., Markowitz, G. S., Appel, G. B., Pogue, V. A., & D’Agati, V. D. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1071566 · Cited by 93
Barraclough, K. A., Er, L., Ng, F., Harris, M., Montaner, J., & Levin, A. (2008) · Nephron Clinical Practice · doi:10.1159/000178978 · Cited by 90
Chang, H. R., & Pella, P. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc061892 · Cited by 82
Acute interstitial nephritis associated with atazanavir, a new protease inhibitor
Brewster, U. C., & Perazella, M. A. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.07.017 · Cited by 79
KOHAN, A. D., Armenakas, N. A., & Fracchia, J. A. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68795-2 · Cited by 73
Atazanavir crystal nephropathy
Izzedine, H., m’rad, M. B., Bardier–Dupas, A., Daudon, M., & Salmon, D. (2007) · AIDS · doi:10.1097/qad.0b013e3282f17503 · Cited by 58
Atazanavir urinary stones in an HIV-infected patient
Pacanowski, J., Poirier, J., Petit, I., Meynard, J., & Girard, P. (2006) · AIDS · doi:10.1097/01.aids.0000247571.88256.90 · Cited by 52
Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection
Wyatt, C. M., & Klotman, P. E. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.2.275 · Cited by 49
Tenofovir-induced kidney injury
Gitman, M. D., Hirschwerk, D. A., Baskin, C., & Singhal, P. C. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.2.155 · Cited by 43
Atazanavir-containing renal calculi in an HIV-infected patient
Anderson, P. L., Lichtenstein, K. A., Gerig, N. E., Kiser, J. J., & Bushman, L. R. (2007) · AIDS · doi:10.1097/qad.0b013e3280c56ae1 · Cited by 42
Cited by
Future challenges for clinical care of an ageing population infected with HIV: a modelling study
Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., Sighem, A. V., de Wolf, F., & Hallett, T. B. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00056-0 · Cited by 908
Sax, P. E., Wohl, D., Yin, M. T., Post, F., DeJesus, E., Saag, M., Pozniak, A., Thompson, M., Podzamczer, D., Molina, J. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60616-x · Cited by 601
Günthard, H. F., Aberg, J. A., Eron, J. J., Hoy, J. F., Telenti, A., Benson, C. A., Burger, D. M., Cahn, P., Gallant, J. E., Glesby, M. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.8722 · Cited by 449
Self-citationAssociation of tenofovir exposure with kidney disease risk in HIV infection
Scherzer, R., Estrella, M., Li, Y., Choi, A. I., Deeks, S. G., Grunfeld, C., & Shlipak, M. G. (2012) · AIDS · doi:10.1097/qad.0b013e328351f68f · Cited by 424
Current status and prospects of HIV treatment
Cihlar, T., & Fordyce, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.004 · Cited by 337
Metadata
- Authors
- Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Gatell, J., Phillips, A. N., Ledergerber, B., & Lundgren, J. D.
- Venue
- AIDS
- Published
- 2010-07-17
- Volume
- 24
- Issue
- 11
- Pages
- 1667-1678
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2080152031
- Cited by
- 406
- References
- 52
- FWCI
- 22.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.